$SXTP
60 Degrees Pharmaceuticals Inc Stock $sxtp

$sxtp Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000121390024028577 Filed on April 01, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$125.0K	$42.71K	$253.6K
YoY Change	109.92%	-91.65%	-50.4%
Cost Of Revenue	$89.56K	$146.3K	$474.6K
YoY Change	-51.32%	-66.17%	9.76%
Gross Profit	$35.41K	-$103.6K	-$221.0K
YoY Change	-128.45%	-231.34%	-380.29%
Gross Profit Margin	28.33%	-242.45%	-87.15%
Selling, General & Admin	$1.130M	$1.690M	$4.242M
YoY Change	144.07%	29.66%	225.36%
% of Gross Profit	3190.13%
Research & Development	$3.095M	$100.2K	$691.8K
YoY Change	1418.27%	-80.93%	31.63%
% of Gross Profit	8741.88%
Depreciation & Amortization	$1.536K	$10.42K	$50.32K
YoY Change	-77.74%	12.77%	53.56%
% of Gross Profit	4.34%
Operating Expenses	$4.225M	$1.791M	$4.934M
YoY Change	533.73%	-2.11%	169.7%
Operating Profit	-$4.189M	-$1.894M	-$5.155M
YoY Change	431.57%	8.21%	194.47%
Interest Expense	-$4.720K	-$138.1K	-$2.724M
YoY Change	-100.43%	-96.94%	-39.53%
% of Operating Profit
Other Income/Expense, Net	$19.68K	-$13.95K	$5.296M
YoY Change	-101.85%	-67.74%	-12348.27%
Pretax Income	-$4.174M	-$2.046M	-$3.814M
YoY Change	24.83%	-66.88%	-38.26%
Income Tax	$438.00	$60.00	$250.00
% Of Pretax Income
Net Earnings	-$4.173M	-$2.131M	-$3.986M
YoY Change	25.06%	-65.52%	-35.51%
Net Earnings / Revenue	-3338.95%	-4990.54%	-1572.12%
Basic Earnings Per Share	-$4.23		-$0.99
Diluted Earnings Per Share	-$4.23	-$0.37	-$1.01
COMMON SHARES
Basic Shares Outstanding	11.57M shares	5.800M shares	3.960M shares
Diluted Shares Outstanding	1.015M shares		3.960M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.577M	$2.142M	$2.142M
YoY Change	8167.44%	708.88%	708.88%
Cash & Equivalents	$1.577M	$2.142M	$2.142M
Short-Term Investments
Other Short-Term Assets	$1.464M	$4.403M	$4.403M
YoY Change	-71.09%	1533.01%	1533.01%
Inventory	$426.0K	$466.2K	$466.2K
Prepaid Expenses
Receivables	$296.4K	$231.3K	$231.3K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.763M	$7.243M	$7.243M
YoY Change	-33.69%	559.02%	559.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$159.6K	$71.28K	$71.28K
YoY Change	2028.45%	109.96%	109.96%
Goodwill
YoY Change
Intangibles	$250.1K	$227.3K
YoY Change	21.19%	38.36%
Long-Term Investments
YoY Change
Other Assets	$404.5K	$242.7K	$242.7K
YoY Change	-71.73%
Total Long-Term Assets	$564.1K	$541.2K	$541.2K
YoY Change	-66.5%	173.03%	173.03%
TOTAL ASSETS
Total Short-Term Assets	$3.763M	$7.243M	$7.243M
Total Long-Term Assets	$564.1K	$541.2K	$541.2K
Total Assets	$4.327M	$7.784M	$7.784M
YoY Change	-41.2%	500.04%	500.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$643.4K	$506.2K	$506.2K
YoY Change	-39.21%	-33.28%	-33.28%
Accrued Expenses		$13.65K	$13.65K
YoY Change		5.0%	5.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due	$8.772K	$8.770K	$8.770K
YoY Change	-98.42%	-99.96%	-99.96%
Total Short-Term Liabilities	$1.219M	$2.835M	$2.835M
YoY Change	-95.78%	-88.15%	-88.15%
LONG-TERM LIABILITIES
Long-Term Debt	$148.7K	$150.3K	$150.3K
YoY Change	-99.4%	-88.17%	-88.17%
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$148.7K	$150.3K	$150.3K
YoY Change	-89.17%	-90.15%	-90.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.219M	$2.835M	$2.835M
Total Long-Term Liabilities	$148.7K	$150.3K	$150.3K
Total Liabilities	$1.368M	$2.914M	$2.914M
YoY Change	-95.48%	-88.29%	-88.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.32M	-$32.58M
YoY Change	4.52%	13.07%
Common Stock	$102.00	$581.00
YoY Change	-57.14%	143.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.035M	$4.870M	$4.870M
YoY Change
Total Liabilities & Shareholders Equity	$4.327M	$7.784M	$7.784M
YoY Change	-41.2%	500.04%	500.04%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.173M	-$2.131M	-$3.986M
YoY Change	25.06%	-65.52%	-35.51%
Depreciation, Depletion And Amortization	$1.536K	$10.42K	$50.32K
YoY Change	-77.74%	12.77%	53.56%
Cash From Operating Activities	-$1.188M	-$63.67K	-$4.543M
YoY Change	279.03%	-3.5%	349.8%
INVESTING ACTIVITIES
Capital Expenditures	$130.6K	$66.56K	$115.9K
YoY Change	620.13%	13.51%	92.73%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$130.6K	-$66.56K	-$115.9K
YoY Change	620.13%	13.51%	92.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$7.586M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-860.0	0.000	6.475M
YoY Change	-100.27%	-100.0%	429.96%
NET CHANGE
Cash From Operating Activities	-1.188M	-63.67K	-4.543M
Cash From Investing Activities	-130.6K	-66.56K	-115.9K
Cash From Financing Activities	-860.0	0.000	6.475M
Net Change In Cash	-1.320M	-130.2K	1.816M
YoY Change	12408.34%	-32.61%	1097.74%
FREE CASH FLOW
Cash From Operating Activities	-$1.188M	-$63.67K	-$4.543M
Capital Expenditures	$130.6K	$66.56K	$115.9K
Free Cash Flow	-$1.319M	-$130.2K	-$4.659M
YoY Change	297.68%	4.5%	335.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3960280	shares
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41719
CY2023	dei	Entity Registrant Name EntityRegistrantName	60 DEGREES PHARMACEUTICALS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2406880
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1025 Connecticut Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	NW Suite 1000
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Washington, D.C
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20036
CY2023	dei	City Area Code CityAreaCode	(202)
CY2023	dei	Local Phone Number LocalPhoneNumber	327-5422
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	11551806	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11570578	shares
CY2023	dei	Auditor Name AuditorName	RBSM LLP
CY2023	dei	Auditor Firm AuditorFirmId	587
CY2023	dei	Auditor Location AuditorLocation	Las Vegas, Nevada
CY2023Q4	us-gaap	Cash Cash	2142485	usd
CY2022Q4	us-gaap	Cash Cash	264865	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	231332	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45965	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4402602	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	200967	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	68629	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	466169	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	518578	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	7242588	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1099004	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57761	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21300	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13517	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12647	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	242647	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	227258	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	164255	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	483422	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	176902	usd
CY2023Q4	us-gaap	Assets Assets	7783771	usd
CY2022Q4	us-gaap	Assets Assets	1297206	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	506206	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	758668	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13650	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13000	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	325000	usd
CY2022Q4	sxtp	Related Party Notes Netincluding Accrued Interest RelatedPartyNotesNetincludingAccruedInterest	195097	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	4276609	usd
CY2023Q4	sxtp	Sbaeid Lincluding Accrued Interest Current SBAEIDLincludingAccruedInterestCurrent	8772	usd
CY2022Q4	sxtp	Sbaeid Lincluding Accrued Interest Current SBAEIDLincludingAccruedInterestCurrent	2750	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	16855887	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2306796	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1129840	usd
CY2022Q4	sxtp	Derivative Liabilities Related Parties DerivativeLiabilitiesRelatedParties	364360	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2835424	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23921211	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	255000	usd
CY2023Q4	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	150251	usd
CY2022Q4	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	160272	usd
CY2022Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	1109783	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	150251	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1525055	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2985675	usd
CY2022Q4	us-gaap	Liabilities Liabilities	25446266	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	78803	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	78803	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	9858040	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	581	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	239	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	27456802	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5164461	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	135561	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	73708	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32580850	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28815148	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4870134	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-23576740	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-72038	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-572320	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4798096	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24149060	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7783771	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1297206	usd
CY2023	us-gaap	Revenues Revenues	253573	usd
CY2022	us-gaap	Revenues Revenues	223208	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	474550	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	432370	usd
CY2023	us-gaap	Gross Profit GrossProfit	-220977	usd
CY2022	us-gaap	Gross Profit GrossProfit	-209162	usd
CY2022	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	288002	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-220977	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	78840	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	691770	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	525563	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4241836	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1303722	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	4933606	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1829285	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5154583	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1750445	usd
CY2023	us-gaap	Interest Expense InterestExpense	2286637	usd
CY2022	us-gaap	Interest Expense InterestExpense	3989359	usd
CY2023	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-399725	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-504613	usd
CY2023	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-37278	usd
CY2022	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-10312	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1231480	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	120683	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	5379269	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-83116	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-43238	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1341033	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4426839	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3813550	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6177284	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-3813800	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-6177784	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-48098	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3936	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3765702	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6181720	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-3813800	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-6177784	usd
CY2023	sxtp	Unrealized Foreign Currency Translation Gain Loss UnrealizedForeignCurrencyTranslationGainLoss	61853	usd
CY2022	sxtp	Unrealized Foreign Currency Translation Gain Loss UnrealizedForeignCurrencyTranslationGainLoss	-2127	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3751947	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-6179911	usd
CY2023	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-48098	usd
CY2022	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	3936	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3703849	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6183847	usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	220714	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3924563	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6183847	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.61
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3960280	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2367729	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-18154484	usd
CY2022	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	29265	usd
CY2022	sxtp	Netloss Income Through May Thirty First Two Thousand Twenty Two NetlossIncomeThroughMayThirtyFirstTwoThousandTwentyTwo	-1947876	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	185335	usd
CY2022	sxtp	Net Foreign Translation Gainloss After June One Two Thousand Twenty Two NetForeignTranslationGainlossAfterJuneOneTwoThousandTwentyTwo	-27138	usd
CY2022	sxtp	Netloss Income After June One Two Thousand Twenty Two NetlossIncomeAfterJuneOneTwoThousandTwentyTwo	-4229908	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24149060	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24149060	usd
CY2023	sxtp	Sharebased Compensation To Vendors For Services SharebasedCompensationToVendorsForServices	5683056	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7989598	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	10128500	usd
CY2023	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	838748	usd
CY2023	sxtp	Net Of Underwriting Discounts And Offering Costs NetOfUnderwritingDiscountsAndOfferingCosts	1266740	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	6235276	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1131771	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	528926	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	163228	usd
CY2023	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-61853	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-3813800	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4798096	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-3813800	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-6177784	usd
CY2023	us-gaap	Depreciation Depreciation	21162	usd
CY2022	us-gaap	Depreciation Depreciation	27648	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	29157	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	5118	usd
CY2023	sxtp	Amortization Of Debt Discount AmortizationOfDebtDiscount	669148	usd
CY2022	sxtp	Amortization Of Debt Discount AmortizationOfDebtDiscount	1090387	usd
CY2023	sxtp	Amortization Of Rou Asset AmortizationOfROUAsset	-50053	usd
CY2022	sxtp	Amortization Of Rou Asset AmortizationOfROUAsset	-46020	usd
CY2023	sxtp	Amortization Of Note Issuance Costs AmortizationOfNoteIssuanceCosts	-67728	usd
CY2022	sxtp	Amortization Of Note Issuance Costs AmortizationOfNoteIssuanceCosts	-74496	usd
CY2023	sxtp	Amortization Of Capitalized Services AmortizationOfCapitalizedServices	-994643	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	212605	usd
CY2023	sxtp	Share Based Compensation Under2022 Equity Incentive Plan ShareBasedCompensationUnder2022EquityIncentivePlan	528926	usd
CY2023	sxtp	Deemed Capital Contribution For Related Party Compensation Expense Note11 DeemedCapitalContributionForRelatedPartyCompensationExpenseNote11	163228	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1231480	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	120683	usd
CY2023	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	37278	usd
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	10312	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	399725	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	504613	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5379269	usd
CY2023	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-160338	usd
CY2022	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	160338	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	185367	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-100397	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	522370	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-24902	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-212747	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10126	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-214734	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	169990	usd
CY2023	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-1265361	usd
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-2685678	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-50273	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-46795	usd
CY2023	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-100000	usd
CY2022	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	425257	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4542910	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1009980	usd
CY2023	us-gaap	Payments For Software PaymentsForSoftware	39982	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	33063	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57623	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18283	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	27070	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-115888	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-60133	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	150420	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	68629	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1047692	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1047692	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6454325	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1131771	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	650000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	800000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	305000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1611111	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	250000	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	185335	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	250000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6474565	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1221706	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-61853	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2127	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1877620	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	149466	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115399	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2142485	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264865	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	179117	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2193	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
CY2023	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	7989598	usd
CY2022	sxtp	Conversion Of Related Party Advance Into Common Stock ConversionOfRelatedPartyAdvanceIntoCommonStock	185335	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	10128500	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	270460	usd
CY2023	sxtp	Capitalized Share Based Payments To Vendors CapitalizedShareBasedPaymentsToVendors	4916555	usd
CY2023	sxtp	Additions To Rou Assets For Lease Renewal AdditionsToROUAssetsForLeaseRenewal	50922	usd
CY2023	sxtp	Additions To Lease Liabilities For Lease Renewal AdditionsToLeaseLiabilitiesForLeaseRenewal	50570	usd
CY2022	sxtp	Conversion Of60 Pllc Member Units To Common Stock ConversionOf60PLLCMemberUnitsToCommonStock	4979365	usd
CY2023	sxtp	Debt Discount Recorded In Connection With Derivative Liabilities DebtDiscountRecordedInConnectionWithDerivativeLiabilities	650000	usd
CY2022	sxtp	Debt Discount Recorded In Connection With Derivative Liabilities DebtDiscountRecordedInConnectionWithDerivativeLiabilities	1105000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	520000	usd
CY2023	sxtp	Stock Issued For Acquisition Of Intangibles StockIssuedForAcquisitionOfIntangibles	33895	usd
CY2023	us-gaap	Notes Issued1 NotesIssued1	301416	usd
CY2023	sxtp	Reclassification Of Liabilityclassified Warrants To Equityclassified ReclassificationOfLiabilityclassifiedWarrantsToEquityclassified	-838748	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. NATURE OF OPERATIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. Currently, 60P’s pipeline under development covers development programs for tick-borne fungal and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Initial Public Offering</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 14, 2023, the Company closed its initial public offering consisting of 1,415,095 units at a price of $5.30 per unit for $6,454,325 in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses paid by the Company at closing (the “IPO”). Each unit consisted of one share of common stock of the Company, par value $0.0001 per share, one tradeable warrant to purchase one share of common stock at an exercise price of $6.095 per share (a “Tradeable Warrant”), and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise price of $6.36 per share (a “Non-tradeable Warrant”). The Tradeable Warrants and Non-Tradeable Warrants are immediately exercisable on the date of issuance and will expire five years from the date of issuance (July 12, 2023 to July 12, 2028).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company granted the underwriters a 45-day over-allotment option to purchase up to 212,265 shares of the Company’s common stock at a price of $5.28 per share and/or 212,265 Tradeable Warrants at a price of $0.01 per Tradeable Warrant and/or 212,265 Non-tradeable Warrants at $0.01 per Non-tradeable Warrant, or any combination thereof (the “Over-Allotment”). On July 13, 2023, the underwriters partially exercised the Over-Allotment and purchased an additional 100,644 Tradeable Warrants and 100,644 Non-tradeable Warrants. The Company also issued to the underwriters warrants to purchase 84,906 shares of the Company’s common stock, at an exercise price of $5.83 per share, equal to 110% of the offering price per unit (the “Representative Warrants”). The Representative Warrants are exercisable for a period of five years from the date of issuance (July 14, 2023 to July 14, 2028).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The units were offered and sold pursuant to the Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023 (the “Registration Statement”) and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective by the SEC on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023. See Note 6 for further details.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Risks and Uncertainties</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company’s ability to obtain regulatory approval of its such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, higher rates of inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, the Company or its partners’ ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on the Company’s business and financial condition, including the Company’s ability to access additional capital on favorable terms, or at all, which could in the future negatively affect the Company’s ability to pursue its business strategy.<b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. This condition, among others, raises substantial doubt about the ability of the Company to continue as a going concern for one year from the date these financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In view of these matters, continuation as a going concern is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and achieve gross profitability from their single marketed product. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as the business achieves profitability or a business combination may be achieved.</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 31, 2023, the Company had cash and cash equivalents totaling $2,142,485, as compared to cash and cash equivalents totaling $264,865 at December 31, 2022. During the twelve months ended December 31, 2023, the Company used cash of $4,542,910 in its operating activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s future results are subject to substantial risks and uncertainties. The Company has operated at a loss for its entire history and there can be no assurance that it will ever achieve or maintain profitability. The Company has historically funded its operations primarily with proceeds from sales of common stock and warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to need to raise additional capital under structures available to the Company, including debt and/or equity offerings, which may not be on favorable terms. The Company would not have sufficient funds to meet its obligations within twelve months from the issuance date of these consolidated financial statements. As such, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt about the Company’s ability to continue as a going concern. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises funds through collaborations, or other similar arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company and/or may reduce the value of its common stock. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market its product candidates even if the Company would otherwise prefer to develop and market such product candidates itself.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also expects to use cash and cash equivalents to fund activities relating to commercial support for its existing product and any future clinical research trials and operating activities. The Company’s future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs; obtaining regulatory approvals and complying with applicable laws and regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and the effect of competing technological and market developments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s capital commitments over the next twelve months include interest obligations on the Company’s debt arrangements of $8,772, $13,650 for payments due under operating lease liabilities, and $506,206 to satisfy accounts payable and accrued expenses.</p>
CY2023Q3	sxtp	Percentage Of Offering Price Per Unit PercentageOfOfferingPricePerUnit	1.10	pure
CY2023Q4	us-gaap	Cash Cash	2142485	usd
CY2022Q4	us-gaap	Cash Cash	264865	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4542910	usd
CY2023Q4	sxtp	Sbaeid Lincluding Accrued Interest Current SBAEIDLincludingAccruedInterestCurrent	8772	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13650	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	506206	usd
CY2023Q4	us-gaap	Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee	1	pure
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Use of Estimates</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, deferred compensation, derivative liabilities, and valuation allowance for the deferred tax asset.</p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	191111	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	162222	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	2306796	usd
CY2023	us-gaap	Taxes Other TaxesOther	250	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Concentrations</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and borrowings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant customers represent any customer whose business makes up 10% of receivables or revenues. At December 31, 2023, significant customers represented 92% of receivables (consisting of three customers and two significant customers at 79% and 13%, respectively) and 93% of total net revenues (consisting of two significant customers at 72% and 21%, respectively). At December 31, 2022, 96% of the Company’s receivables (consisting of three customers and two significant customers at 66% and 30%), and 100% of total net revenues (consisting of four customers and three significant at 40%, 39% and 14%, respectively).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended in 2022 and near-term receivables and revenues from the government are not currently anticipated to be significant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, 0% (85% at December 31, 2022) of the Company’s non-related party debt is held by Knight Therapeutics, previously the senior secured lender and also a publicly traded Canadian company.</p>
CY2023	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0	pure
CY2022	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.85	pure
CY2023	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Revenue Recognition</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue in accordance with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from product sales are recorded at the net sales price, or “transaction price,” which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives the majority of its revenues from sales of its Arakoda™ product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for 60P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.</p>
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	691770	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	525563	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2306796	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1494200	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1494200	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Reclassifications</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated results of operations and comprehensive loss, shareholders’ and members’ equity (deficit), or cash flows.</p>
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	397487	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	278987	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	97486	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	187182	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	183943	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	466169	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	678916	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	160338	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	466169	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	518578	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	205825	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	148202	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	148064	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	126902	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57761	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21300	usd
CY2023	us-gaap	Depreciation Depreciation	21162	usd
CY2022	us-gaap	Depreciation Depreciation	27648	usd
CY2023Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	185595	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	145613	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	79248	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	27070	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	264843	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	172683	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	37585	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8428	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	227258	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	164255	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29157	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5118	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts	93545	usd
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5
CY2022Q4	sxtp	Percentage Of Share Issued And Outstanding PercentageOfShareIssuedAndOutstanding	0.61	pure
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31447	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	31447	shares
CY2023Q3	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	214934	shares
CY2023Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	45560	shares
CY2022Q2	sxtp	Bridge Warrants Exercisable Into Common Stock BridgeWarrantsExercisableIntoCommonStock	231917	shares
CY2023Q2	sxtp	Bridge Warrants Exercisable Into Common Stock BridgeWarrantsExercisableIntoCommonStock	231917	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	151991	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	151991	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.83
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.83
CY2022Q2	sxtp	Percentage Of Ipo Price PercentageOfIPOPrice	1.10	pure
CY2023Q2	sxtp	Percentage Of Ipo Price PercentageOfIPOPrice	1.10	pure
CY2023	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	1131771	usd
CY2023	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0	pure
CY2023	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.06	pure
CY2020Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	100000	usd
CY2022Q2	us-gaap	Deferred Compensation Cashbased Arrangements Liability Classified Noncurrent DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent	60000	usd
CY2022Q2	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	400000	usd
CY2022Q2	us-gaap	Deferred Compensation Cash Based Arrangements Liability Current DeferredCompensationCashBasedArrangementsLiabilityCurrent	100000	usd
CY2022Q2	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	245000	usd
CY2022Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	100000	usd
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	57198	usd
CY2022Q2	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	12500	usd
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	1	pure
CY2022Q2	us-gaap	Deferred Compensation Cash Based Arrangements Liability Current DeferredCompensationCashBasedArrangementsLiabilityCurrent	38900	usd
CY2022Q2	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	60000	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	65000	shares
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Exercise Price DeferredCompensationArrangementWithIndividualExercisePrice	5
CY2022Q4	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	325000	usd
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	65000	shares
CY2022Q4	us-gaap	Loans Payable LoansPayable	20596595	usd
CY2023	us-gaap	Long Term Debt Maturities Repayment Terms LongTermDebtMaturitiesRepaymentTerms	30 days
CY2023Q4	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	120683	usd
CY2023	us-gaap	Interest Costs Incurred InterestCostsIncurred	1767	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	52628	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4955	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	66558	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	115546	usd
CY2022Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	214934	shares
CY2022Q1	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	223077	usd
CY2022Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	17965670	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	16855887	usd
CY2022Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	1109783	usd
CY2023	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax	614670	usd
CY2023Q2	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	8472	usd
CY2023Q2	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.90	pure
CY2023	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	79926	shares
CY2023	sxtp	Initial Public Offering Discount Percentages InitialPublicOfferingDiscountPercentages	0.15	pure
CY2023	sxtp	Common Stock Outstanding Percentages CommonStockOutstandingPercentages	0.199	pure
CY2023	us-gaap	Payments For Fees PaymentsForFees	10000000	usd
CY2023	us-gaap	Management Fee Expense ManagementFeeExpense	30000	usd
CY2023Q4	sxtp	Cumulative Dividend Percentage CumulativeDividendPercentage	0.06	pure
CY2023Q4	sxtp	Common Stock Ownership Percentage CommonStockOwnershipPercentage	0.199	pure
CY2022Q1	sxtp	Equal Royalty Pay To Lender Percentage EqualRoyaltyPayToLenderPercentage	3.5	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	839887	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	21520650	usd
CY2023	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	-5379269	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	1293549	usd
CY2023	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	17434930	usd
CY2023	sxtp	Description Of Knight Debt Conversion Agreement DescriptionOfKnightDebtConversionAgreement	As a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement, the cumulative outstanding principal as of March 31, 2022 converted to 1,108,337 shares of common stock (representing 19.9% ownership of the Company’s common stock after giving effect to the IPO). In addition, the entirety of the accumulated interest as of March 31, 2022 converted into 80,965 shares of Series A Preferred Stock at the conversion rate detailed above, in full satisfaction of the Company’s obligations with respect to the accumulated interest. Upon consummation of the IPO and under the terms of the Knight Debt Conversion Agreement, the Company became obligated to the contingent milestone payments and the accumulated Royalty discussed above, which value was included in the reacquisition price of the debt upon extinguishment. The Company recognized a final mark-to-market adjustment of $6,105,066 to adjust the Convertible Knight Loan to its fair value on the date of settlement, and as a result, no gain or loss was recognized on the debt extinguishment.
CY2019Q2	us-gaap	Debt Current DebtCurrent	3000000	usd
CY2019Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2100000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	279061	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3000000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	279061	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	2720939	usd
CY2022Q4	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	1555670	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	4276609	usd
CY2022Q4	us-gaap	Interest Paid Net InterestPaidNet	731	usd
CY2023Q4	sxtp	Sbaeid Lincluding Accrued Interest Current SBAEIDLincludingAccruedInterestCurrent	8772	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	150251	usd
CY2022Q4	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	2750	usd
CY2022Q4	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	160272	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	683	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3228	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	3342	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	142747	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2023Q1	us-gaap	Other Short Term Investments OtherShortTermInvestments	200000	usd
CY2023Q2	us-gaap	Other Short Term Investments OtherShortTermInvestments	50000	usd
CY2023Q2	us-gaap	Other Short Term Investments OtherShortTermInvestments	250000	usd
CY2022Q2	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	1483888	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	979275	usd
CY2022Q2	us-gaap	Derivative Cost Of Hedge DerivativeCostOfHedge	504613	usd
CY2023Q2	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	954725	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	555000	usd
CY2023Q2	us-gaap	Derivative Cost Of Hedge DerivativeCostOfHedge	399725	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1494200	usd
CY2023	sxtp	Fair Value Mark To Market Adjustment FairValueMarkToMarketAdjustment	-2834	usd
CY2023	sxtp	Fair Value Commitment Date FairValueCommitmentDate	954725	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	-149542	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1457801	usd
CY2023	sxtp	Reclassification Of Liabilityclassified Warrants To Equityclassified ReclassificationOfLiabilityclassifiedWarrantsToEquityclassified	-838748	usd
CY2023	sxtp	Derivative Instrument Recognition Of Contingent Milestone Liability DerivativeInstrumentRecognitionOfContingentMilestoneLiability	2117142	usd
CY2023	sxtp	Fair Value Mark To Market Adjustment Contingent Milestone Payment FairValueMarkToMarketAdjustmentContingentMilestonePayment	189654	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	2306796	usd
CY2022	sxtp	Fair Value Commitment Date FairValueCommitmentDate	1483888	usd
CY2022	sxtp	Fair Value Mark To Market Adjustment FairValueMarkToMarketAdjustment	10312	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1494200	usd
CY2023Q4	us-gaap	Price Risk Derivative Liabilities At Fair Value PriceRiskDerivativeLiabilitiesAtFairValue	37278	usd
CY2022Q4	us-gaap	Price Risk Derivative Liabilities At Fair Value PriceRiskDerivativeLiabilitiesAtFairValue	10312	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3006861	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-5807367	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-806689	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-369917	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3813550	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6177284	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	250	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	500	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	250	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	500	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-800846	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1297230	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-364618	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.096	pure
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-478515	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.077	pure
CY2023	sxtp	Effective Income Tax Rate Reconcilation Impact Of Non Us Earnings Amount EffectiveIncomeTaxRateReconcilationImpactOfNonUSEarningsAmount	-33994	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.009	pure
CY2022	sxtp	Effective Income Tax Rate Reconcilation Impact Of Non Us Earnings Amount EffectiveIncomeTaxRateReconcilationImpactOfNonUSEarningsAmount	-33897	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.005	pure
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	280654	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.074	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2023	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1	1129646	usd
CY2023	sxtp	Effective Income Tax Rate Reconciliation Change In Fair Value Of Promissory Note Rate EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPromissoryNoteRate	0.296	pure
CY2022	sxtp	Effective Income Tax Rate Reconciliation Change In Fair Value Of Promissory Note Rate EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPromissoryNoteRate	0	pure
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	304962	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.08	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0	pure
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2042657	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.536	pure
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	683359	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.111	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-298919	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.078	pure
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1126783	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.182	pure
CY2023	sxtp	Tax Reconciliation Not Required TaxReconciliationNotRequired	250	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001	pure
CY2022	sxtp	Tax Reconciliation Not Required TaxReconciliationNotRequired	500	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3453126	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3338726	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	1058	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	189893	usd
CY2023Q4	sxtp	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	3756	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	94034	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3741867	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3338726	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3043135	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3338726	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	698732	usd
CY2023Q4	sxtp	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	-3719	usd
CY2023Q4	sxtp	Deferred Tax Liabilitie Prepaid Expenses DeferredTaxLiabilitiePrepaidExpenses	695013	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	698732	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	295591	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	6339101	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	6338851	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	5807867	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	5807367	usd
CY2023	sxtp	Annual Taxable Income AnnualTaxableIncome	0.80	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	6835123	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	6560235	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	192371	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1543803	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1736174	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	187200	usd
CY2023Q3	us-gaap	Deferred Compensation Arrangement With Individual Shares Authorized For Issuance DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance	40000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.16
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0433	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.10	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y2M4D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	119246	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	740000	shares
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.3
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	256000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.87
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	256000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.87
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	256000	shares
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	222480	usd
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	256000	shares
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	776471	shares
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	0	shares
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	242647	usd
CY2023	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	163228	usd
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.15	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	13992	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13992	usd
CY2023Q4	us-gaap	Receivable With Imputed Interest Discount ReceivableWithImputedInterestDiscount	342	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13650	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13650	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y3M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.15	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	55084	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	51894	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	9434	shares
CY2015Q3	sxtp	Licensed Technology Term LicensedTechnologyTerm	P20Y
CY2015Q3	sxtp	Annual Royalty Payment Percentage AnnualRoyaltyPaymentPercentage	0.05	pure
CY2015Q3	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	75000	usd
CY2015Q3	us-gaap	Gain Loss On Sales Of Loans Net GainLossOnSalesOfLoansNet	6000000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	75000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	789136	shares
CY2023Q4	us-gaap	Share Price SharePrice	0.385
CY2023	sxtp	Pre Funded Warrants PreFundedWarrants	149862	shares
CY2023	sxtp	Pre Funded Warrants Per Price PreFundedWarrantsPerPrice	0.375
CY2023	sxtp	Percentage Of Warrants Underlying Units PercentageOfWarrantsUnderlyingUnits	0.15	pure
CY2023	sxtp	Percentage Of Common Shares PercentageOfCommonShares	0.06	pure
CY2023	sxtp	Percentage Of Offering Price Per Unit PercentageOfOfferingPricePerUnit	1.10	pure
CY2023	us-gaap	Underwriting Income Loss UnderwritingIncomeLoss	1900000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent		usd
CY2023Q4	sxtp	Related Party Notes Netincluding Accrued Interest RelatedPartyNotesNetincludingAccruedInterest		usd
CY2023Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent		usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent		usd
CY2023Q4	sxtp	Derivative Liabilities Related Parties DerivativeLiabilitiesRelatedParties		usd
CY2023Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent		usd
CY2023Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2367729	shares
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023	sxtp	Cancellation Of Common Stock CancellationOfCommonStock		usd
CY2023	sxtp	Voluntary Conversion Of Series A Preferred Stock Into Common Stock VoluntaryConversionOfSeriesAPreferredStockIntoCommonStock		usd
CY2023	sxtp	Contribution From Noncontrolling Interest ContributionFromNoncontrollingInterest		usd
CY2022	sxtp	Amortization Of Capitalized Services AmortizationOfCapitalizedServices		usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	sxtp	Share Based Compensation Under2022 Equity Incentive Plan ShareBasedCompensationUnder2022EquityIncentivePlan		usd
CY2022	sxtp	Deemed Capital Contribution For Related Party Compensation Expense Note11 DeemedCapitalContributionForRelatedPartyCompensationExpenseNote11		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
CY2023	sxtp	Conversion Of Related Party Advance Into Common Stock ConversionOfRelatedPartyAdvanceIntoCommonStock		usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2022	sxtp	Capitalized Share Based Payments To Vendors CapitalizedShareBasedPaymentsToVendors		usd
CY2022	sxtp	Additions To Rou Assets For Lease Renewal AdditionsToROUAssetsForLeaseRenewal		usd
CY2022	sxtp	Additions To Lease Liabilities For Lease Renewal AdditionsToLeaseLiabilitiesForLeaseRenewal		usd
CY2023	sxtp	Conversion Of60 Pllc Member Units To Common Stock ConversionOf60PLLCMemberUnitsToCommonStock		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	sxtp	Stock Issued For Acquisition Of Intangibles StockIssuedForAcquisitionOfIntangibles		usd
CY2022	us-gaap	Notes Issued1 NotesIssued1		usd
CY2022	sxtp	Reclassification Of Liabilityclassified Warrants To Equityclassified ReclassificationOfLiabilityclassifiedWarrantsToEquityclassified		usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials		usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves		usd
CY2023Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure		usd
CY2023Q4	us-gaap	Notes Payable NotesPayable		usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent		usd
CY2023Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes		usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet		usd
CY2023Q4	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts		usd
CY2023Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent		usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths		usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo		usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities		usd
CY2023Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#DerivativeLiabilitiesCurrent
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential		usd
CY2022	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1		usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts		usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment		usd
CY2022Q4	sxtp	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	sxtp	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset		usd
CY2022Q4	sxtp	Deferred Tax Liabilitie Prepaid Expenses DeferredTaxLiabilitiePrepaidExpenses		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense		usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense		usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001946563

Files In Submission

Name	View Source	Status
0001213900-24-028577-index-headers.html	Edgar Link	pending
0001213900-24-028577-index.html	Edgar Link	pending
0001213900-24-028577.txt	Edgar Link	pending
0001213900-24-028577-xbrl.zip	Edgar Link	pending
ea0202353-10k_60degree.htm	Edgar Link	pending
ea020235301ex31-1_60degree.htm	Edgar Link	pending
ea020235301ex31-2_60degree.htm	Edgar Link	pending
ea020235301ex32-1_60degree.htm	Edgar Link	pending
ea020235301ex32-2_60degree.htm	Edgar Link	pending
ea020235301ex4-1_60degrees.htm	Edgar Link	pending
ea020235301ex97-1_60degree.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
ea0202353-10k_60degree_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sxtp-20231231.xsd	Edgar Link	pending
sxtp-20231231_def.xml	Edgar Link	unprocessable
sxtp-20231231_lab.xml	Edgar Link	unprocessable
sxtp-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
sxtp-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SXTP
60 Degrees Pharmaceuticals Inc Stock $sxtp

2024 Q2 Form 10-K Financial Statement

#000121390024028577 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SXTP 60 Degrees Pharmaceuticals Inc Stock $sxtp

2024 Q2 Form 10-K Financial Statement

#000121390024028577 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SXTP
60 Degrees Pharmaceuticals Inc Stock $sxtp